WO2005032542A1 - 空胞化毒素中和剤 - Google Patents
空胞化毒素中和剤 Download PDFInfo
- Publication number
- WO2005032542A1 WO2005032542A1 PCT/JP2004/014979 JP2004014979W WO2005032542A1 WO 2005032542 A1 WO2005032542 A1 WO 2005032542A1 JP 2004014979 W JP2004014979 W JP 2004014979W WO 2005032542 A1 WO2005032542 A1 WO 2005032542A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- proanthocyanidins
- toxin
- active ingredient
- neutralizing agent
- hop
- Prior art date
Links
- 239000003053 toxin Substances 0.000 title claims abstract description 78
- 231100000765 toxin Toxicity 0.000 title claims abstract description 78
- 230000003472 neutralizing effect Effects 0.000 title claims abstract description 50
- 239000003795 chemical substances by application Substances 0.000 title claims description 55
- 239000003814 drug Substances 0.000 claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 230000000694 effects Effects 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims abstract description 12
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 11
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 11
- 229920002770 condensed tannin Polymers 0.000 claims description 31
- 230000002477 vacuolizing effect Effects 0.000 claims description 25
- 235000008694 Humulus lupulus Nutrition 0.000 claims description 20
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 6
- 230000003449 preventive effect Effects 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 208000010643 digestive system disease Diseases 0.000 abstract description 4
- 235000013399 edible fruits Nutrition 0.000 abstract description 4
- 229920001991 Proanthocyanidin Polymers 0.000 abstract description 2
- 108700012359 toxins Proteins 0.000 description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- 241000218228 Humulus Species 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 29
- 244000025221 Humulus lupulus Species 0.000 description 23
- 239000000126 substance Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 239000000843 powder Substances 0.000 description 17
- 239000012528 membrane Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000000108 ultra-filtration Methods 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 241000220225 Malus Species 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 150000008442 polyphenolic compounds Chemical class 0.000 description 10
- 235000013824 polyphenols Nutrition 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 208000005718 Stomach Neoplasms Diseases 0.000 description 9
- 235000021016 apples Nutrition 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 206010017758 gastric cancer Diseases 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 201000011549 stomach cancer Diseases 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- -1 acetate nitrile Chemical class 0.000 description 7
- 235000019658 bitter taste Nutrition 0.000 description 7
- 229920003002 synthetic resin Polymers 0.000 description 7
- 239000000057 synthetic resin Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000009965 odorless effect Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 235000013405 beer Nutrition 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 4
- 101000597253 Clostridium novyi Phospholipase C Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 description 4
- 206010038389 Renal cancer Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000014510 cooky Nutrition 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- 201000010982 kidney cancer Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000007882 Gastritis Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000000718 duodenal ulcer Diseases 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 201000005917 gastric ulcer Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229940126409 proton pump inhibitor Drugs 0.000 description 3
- 239000000612 proton pump inhibitor Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000003934 vacuole Anatomy 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000007336 cyanidin Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical group C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 241000218235 Cannabaceae Species 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229930182622 Rubrin Natural products 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000003048 aphrodisiac agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 208000017215 gastric mucosa-associated lymphoid tissue lymphoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004317 gizzard Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000021577 malt beverage Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000010451 perlite Substances 0.000 description 1
- 235000019362 perlite Nutrition 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Definitions
- the present invention contains, as an active ingredient, proanthocyanidins having an effect of detoxifying vacuolated toxin produced by Helicopauc pulpili, particularly preferably proanthocyanidins obtained from apples or hops.
- Hops are a perennial plant of the hemp family, and their cones (matures of unfertilized female flowers) are generally called hops. Hops have other parts, such as leaves, vines and roots, in addition to the flower part.
- the rubulin part (yellow granules formed at the base of the inner bract of cones) present in the hop cones is the main bitterness and aroma of hops, and along with yeast and malt in beer brewing. It is an important beer ingredient.
- Hops are commonly used as sedatives and anti-aphrodisiacs in folk medicine. Hop bracts are hop cones excluding the lubricated portion and are not useful for beer brewing. In some cases, they are removed during brewing and are produced as a by-product. At that time, hop bracts have not been found to be any particularly effective use other than being used as fertilizer for soil improvement, and the development of higher value-added uses is desired.
- Patent Documents 1, 2, 3, 4, 5, and 6 filed by the applicant of the present invention disclose hops, particularly polyfetools derived from hop bracts, for their antioxidant effect, foam stabilizing effect on malt beverages, and piles. It has been confirmed to have caries, deodorant, cancer cell metastasis inhibitory and topoisomerase inhibitory effects. Further, Patent Document 7 confirms that the compound has a neutralizing effect on a protein toxin having RNA-glycosidase activity or ADP-ribosyllaniferase activity.
- H. pylori is a spiral-shaped gram-negative bacillus whose presence has been reported by Warren and Marshall (Non-Patent Document 1). It has been clarified to be deeply involved in the development of gastrointestinal diseases such as gastritis, gastric ulcer, and duodenal ulcer (see Non-Patent Documents 2, 3, and 4). In addition, since more than 90% of gastric cancer patients are carriers of H. pylori, it is highly likely that H. pylori is involved in the development of stomach cancer. It is a carcinogen of gastric cancer. "
- anti-ulcer drugs such as sofacolcon and prounothol; proton pump inhibitors (PPI) such as omeprazole and lansoprazole; gastric acid secretion suppression such as famotidine and cimetidine Agents (H2 pro-force) have been used.
- PPI proton pump inhibitors
- H2 pro-force gastric acid secretion suppression
- these drugs do not have an effect of suppressing the growth of H. pylori and are symptomatic drugs for ulcerative diseases. Therefore, even after the ulcer disease is cured by the above-mentioned drugs, the H. pylori remains in the stomach, and the recurrence rate within one year after the treatment is 80-90% It had the disadvantage of being high.
- Patent Document 1 Japanese Patent Application Laid-Open No. H09-9-0292177
- Patent Document 2 Japanese Patent Application Laid-Open No. 09-1636969
- Patent Document 3 Japanese Patent Application Laid-Open No. 09-2959544
- Patent Document 4 Japanese Patent Application Laid-Open No. H10-10-0252232
- Patent Document 5 Japanese Unexamined Patent Application Publication No. 2000-32027
- Patent Document 6 Japanese Patent Publication No. 2 0 0 1 0 3 9 8 8 6
- Patent Document 7 International Publication No. 02/077826 pamphlet
- Non-Patent Document 1 Lancet, 1273-1275 (1983)
- Non-Patent Document 2 Med.J.Aust., 142, 436 (1985)
- Non-Patent Document 3 Gastroenterology, 102, 1575 (1992)
- Non-Patent Document 4 N. Engl. Med., 328, 308 (1993)
- Non-Patent Document 5 Infect. Immun. 63, 4154-4160 (1995)
- an object of the present invention is to prevent, prevent or treat gastrointestinal diseases involving Helicobacter pylori, which have few side effects and no resistant bacteria, and neutralize the empty toxin produced by H. pylori. It is to provide a medicinal product, a quasi-drug, and a food and drink having an effect.
- the present inventors have tried to solve the problem by finding a factor that does not kill H. pylori but detoxifies the vacuolated toxin produced by H. pylori. If an effective non-toxic dangling factor of the vacuole dang is found, its medical and industrial significance is immeasurable.
- the present inventors have conducted intensive studies and found that a type of polyphenols present in hops and apples effectively detoxifies the vacuole-forming toxin produced by H. pylori, The present invention has been completed.
- This polyphenol is particularly abundant in immature fruits of apples and bracts of hops.
- This polyphenol contained in hops is adsorbed by resins that have an affinity for polyphenol, such as styrene divinylbenzene resin, and has the property of not permeating through an ultrafiltration membrane with a cut-off molecular weight of 1,000 or more. It is considered to be bronthocyanidins that hydrolyze to produce cyanidin when heated in an alcohol solution containing about 5% hydrochloric acid.
- These proanthocyanidins give a chromatogram as shown in FIG. 1 in GPC (gel permeation chromatography) analysis, and give an absorbance distribution as shown in FIG. 2 in absorbance analysis.
- this polyphenol contained in apple is also adsorbed by resins that have an affinity for polyphenol such as styrene-divinylbenzene resin, and when heated in an alcohol solution containing about 5% hydrochloric acid, it is hydrolyzed to cyanidin.
- resins that have an affinity for polyphenol such as styrene-divinylbenzene resin, and when heated in an alcohol solution containing about 5% hydrochloric acid, it is hydrolyzed to cyanidin.
- the present invention relates to a neutralizing agent for vacuolar gall toxin containing proanthocyanidins, particularly preferably proanthocyanidins derived from hops or apples, as an active ingredient.
- Substances that neutralize vacuolated toxin include 5-fluoro-2--2- (3-phenylpropylamino) benzene phloretin, and some borifhenols, which are responsible for the current on the cell membrane caused by vacuolated toxin. Inhibiting changes has been shown by Tombola et al. (Imbola F. et al., FEBS Lett. 543, 184-189 (2003)). However, it is reported in the same literature that substances that suppress changes in the current on the cell membrane in these systems are not related to inhibition of intracellular vacuolation by vacuolating toxin or neutralization of toxicity to cells. It is stated. In these documents, compounds that are shown as substances that suppress changes in current on cell membranes are compounds that are not proanthocyanidins, although they are bolifenols.
- Figure 1 shows the results of GPC (gel permeation chromatography) analysis of hop-derived proanthocyanidins.
- FIG. 2 is a diagram showing the absorbance distribution of hop-derived proanthocyanidins.
- FIG. 3 is a diagram showing the results of HPLC analysis of proanthocyanidins derived from hops.
- FIG. 4 is a diagram showing non-toxic illness of vacuolar venom toxin in cultured cells of human gastric cancer cells AZ-521. (Example 13)
- FIG. 5 is a view showing the non-toxic illness of vacuolar venom in cultured cells of human kidney cancer cells G401. (Example 13)
- FIG. 6 is a diagram showing the inhibition of the uptake of vacuolar gamma toxin into cells of cultured human gastric cancer cells AZ-521. (Example 14)
- FIG. 7 is a diagram showing the inhibition of the incorporation of vacuolar gamma toxin into cells of cultured human kidney cancer cells G401. (Example 14)
- vacuolating toxin neutralizing agent of the present invention in addition to immature fruits of apples, vine bracts of hops are suitable, but in particular, whole apple hops should be used without separating each part. You can also.
- Hop bracts are obtained by removing the rubulin part from hop cones.
- hop bracts are obtained by crushing hop cones and removing the rubrin part by sieving.
- hop cones are formed into pellets without removing hop bracts that are not useful for beer brewing. They tend to be used for brewing. Accordingly, the raw material of the present invention is not particularly limited as long as it contains hop bracts, and there is no problem even if hop cones or hop pellets containing hop bracts are used as raw materials.
- hop vines, bracts, hob cones and hop pellets containing hop bracts, or those containing those hop plant parts are used as raw materials.
- This is extracted with water or an aqueous solution of an organic solvent miscible with water such as alcohol, acetone, or acetonitrile of 8 O v / v% or less.
- a suitable example is ethanol containing 50 v / v% or less of hydrated ethanol.
- the ratio between the raw material and the extraction solvent is preferably about 1:20 to 100 (weight ratio), and the extraction is performed at 4 to 95 ° (:, with stirring, for about 20 to 60 minutes.
- An extract is obtained by filtration, and if necessary, a filter aid such as perlite can be used.
- the solvent is removed from the extract thus obtained by a conventional method such as concentration, lyophilization, spray drying, etc., and the vacuolated toxin neutralizing agent can be obtained as a powder.
- the vacuolated toxin neutralizing agent obtained here can be sufficiently used practically, but if necessary, its purification degree can be further increased by the following method using an adsorption resin. However, this step is merely a step for increasing the degree of purification of the vacuolating toxin neutralizing agent, and can be omitted if unnecessary.
- the extract is treated with granulated synthetic resin having an affinity for polyphenols, and the vacuolating toxin neutralizing agent is concentrated.
- the hop extract may be passed through a column filled with granular synthetic resin, and after sufficiently washing the column, the neutralizing agent for the vacuolar gamma toxin adsorbed on the column may be eluted. Then, the granular resin can be immersed in a hop extract and batch-processed.
- the hop extract When adsorbing the vacuolating toxin neutralizing agent to the synthetic resin, cool the hop extract to room temperature of 15 to 30 ° C, and if necessary, reduce the pressure in order to increase the adsorption efficiency. It is desirable to lower the concentration of the organic solvent in the extract in advance, for example.
- the material of the synthetic adsorbent hydroxypropylated dextran, KK-functional vinyl polymer, styrene-divinylbenzene polymer and the like can also be used.
- the synthetic resin is washed, and the degree of purification of the vacuolating toxin neutralizing agent can be further increased.
- a solvent used for washing water or an aqueous solution of 1 to 10 w / w% ethanol is suitable, and it is desirable to wash using a solvent amount of about 1 to 10 times the amount of the resin.
- the vacuolating toxin neutralizing agent is desorbed and eluted from the synthetic resin to which polyphenols are adsorbed.
- aqueous alcohol, aqueous acetone, aqueous acetate nitrile and the like can be used, and particularly preferable examples include an aqueous ethanol solution of 30 w / w% or more or ethanol.
- the flow rate of the elution solvent is preferably about 2 to 6 times the amount of the resin.
- the solvent is removed from the obtained eluate by a usual method such as concentration, freeze-drying, spray-drying, etc., and the neutralizing agent for vacuolar gamma toxin can be obtained as a powder. Also, during concentration under reduced pressure, alcohol, acetone, acetonitrile, etc. can be collected and reused.
- the used synthetic resin can be repeatedly used after being washed with an alcohol aqueous solution of 8 O v / v% or more, an aqueous solution of sodium hydroxide of about 0.05 N or the like.
- the thus-obtained neutralizing agent for vacuolated toxin can be used as it is, but the purification degree can be further increased by a method using an ultrafiltration membrane as described below. However, this step is merely a step for increasing the degree of purification of the vacuolating toxin neutralizing agent, and can be omitted if unnecessary.
- the vacuolating toxin neutralizing agent obtained by the above method is dissolved in water or an organic solvent miscible with water, and treated with an ultrafiltration membrane having a molecular weight cut-off of 1,000 or more.
- the material of the membrane can be used without any particular limitation, such as cellulose, cellulose acetate, polysulfone, polypropylene, polyester, polyethersulfone, and PVDF, which are usually used as materials for ultrafiltration membranes. . If the molecular weight cut-off is 1,000 or more, it can be used without any problem.However, if a membrane with an excessively high molecular weight is used, the yield will be extremely reduced, and if the molecular weight cut-off is small, the processing time will be short.
- an ultrafiltration membrane having a molecular weight cutoff of about 5,000 to 50,000 is suitable.
- the treatment depends on the type of extraction solvent and the ratio of extraction solvent to hops or hop bracts, but is carried out until the amount of the remaining liquid is about 1/1/10 at the start of the treatment: L / 100. It is desirable.
- the pressure at that time depends on the ultrafiltration membrane and the filtration device, but is preferably about 0.1 to 10.0 kg / cm 2 . If necessary, once processed, the remaining solution can be diluted again with a suitable solvent such as water, and then reprocessed in the same manner to increase the degree of purification.
- the solvent in the obtained upper residue is removed by a conventional method such as concentration, freeze-drying, spray-drying or the like, and the neutralizing agent for vacuolar gallantoxin can be obtained as a powder.
- concentration concentration, freeze-drying, spray-drying or the like
- the neutralizing agent for vacuolar gallantoxin can be obtained as a powder.
- alcohol, acetone, acetonitrile, etc. can be collected and reused.
- the thus-obtained neutralizing agent for vaccinated toxin is an odorless, brownish or pale yellow powder having a slightly bitter taste, and is used as a synthetic resin having an affinity for polyphenol. It is a proanthocyanidin that is adsorbed and does not pass through the membrane when treated with an ultrafiltration membrane with a molecular weight cut-off of 1,000 or more.
- the yield is 0.5 to 20.0 w / w% in terms of hop bract weight, and 0.5 to I5.0 w / w% in terms of hop cone weight.
- a method for producing a vacuolated toxin neutralizing agent from apples is as follows: apple fruits, preferably unripe apples, are squeezed by pressing to form a solution containing a vacuolated toxin neutralizing agent, and the solution is concentrated. It can be used as a powder by ordinary methods such as freeze-drying and spray-drying. Further, if necessary, the neutralizing agent for vacuolar mite may be purified using a column or the like packed with a granular resin or the like having an affinity for polyphenol to increase the degree of purification. This step is the same operation as the step of concentrating and purifying the neutralizing agent for the vacuolar mite toxin obtained from hops.
- the vacuolated toxin neutralizing agent thus obtained can be formulated together with commonly used carriers, auxiliaries, additives, etc., and can be used as a medicinal product as an oral or parenteral product according to a conventional method. It can also be mixed with food materials to make food and drink. Pharmaceuticals include tablets, capsules, granules and syrups as oral preparations, parenteral preparations for external use such as ointments, creams and solutions, and injections such as sterile solutions and suspensions. When these products are administered to the human body as a medicine, 2 mg to 500 mg is administered once or several times a day, that is, in a total daily dose of 2 mg to 100 mg, and the effect can be sufficiently exerted.
- compositions containing the vacuolating toxin neutralizing agent of the present invention can take the required unit dosage form together with a physiologically acceptable vehicle, carrier, excipient, integrator, stabilizer, flavoring agent, etc. .
- the adjuvants mixed with tablets and capsules are as follows. Binders such as tragacanth, acacia, corn starch, gelatin, excipients such as microcrystalline cellulose, corn starch, whole gelatinized starch, leavening agents such as alginic acid, lubricants such as magnesium stearate, Sweeteners such as sugar, lactose, saccharin, flavoring agents such as peppermint, coconut oil, and cellulose.
- the above materials may further contain a liquid carrier such as oil and fat, and the other materials may be used as a coating material or the physical form of the preparation may be changed by another method.
- a liquid carrier such as oil and fat
- the other materials may be used as a coating material or the physical form of the preparation may be changed by another method.
- tablets may be coated with shellac or sugar You can.
- a syrup or elixir may contain sucrose as a sweetening agent, methyl or propylparabens as preservatives, a dye and flavoring such as cellulose or orange flavor.
- Sterile compositions for injections dissolve the active substance in vehicles such as water for injection, naturally occurring vegetable oils such as sesame oil, coconut oil, peanut oil, cottonseed oil, or sword beefgur such as ethylolate Alternatively, it can be formulated by a usual method of suspending. In addition, buffers, preservatives, antioxidants, and the like can be added as necessary. As external preparations, vaseline, paraffin, oils and fats, lanolin, macrogol and the like can be used, and ointments and creams can be prepared in a usual manner.
- the food and beverage containing the vacuolating toxin neutralizing agent of the present invention may be in the form of the above-mentioned preparations, but may be prepared in the form of candy, rice crackers, cookies, beverages, etc. It can also be processed and manufactured by the method.
- health foods and functional foods are used for disease prevention and health maintenance, they are ingested as a processed product containing 5 mg to 500 mg as a daily dose divided into several times a day.
- the neutralizing agent for vacuolar toxin When adding a neutralizing agent for vacuolar toxin to these foods and drinks, the neutralizing agent for vacuolar toxin may be added as it is in a powder form. It is desirable to add a 1% to 2% aqueous solution or an alcohol aqueous solution or an alcohol solution, and to add them to foods and drinks so that the final concentration is 1 to: 10,000 ppm, preferably 100 to 5000 ppm.
- the neutralizing agent for vacuolated toxin of the present invention is used as a preventive agent when used for the purpose of preventing the digestive disease, and as a preventive agent when used for the purpose of preventing the recurrence of the digestive disease once cured.
- a preventive agent for recurrence it can be used as a disinfectant when used for treating the digestive disease by removing H. pylori.
- the bactericidal agent of the present invention may be used alone, or a proton pump inhibitor and / or an antibiotic may be used. Substances may be used in combination.
- the daily dose of the vacuolating toxin-neutralizing agent of the present invention is appropriately selected depending on its usage, the age of the patient, gender and other conditions, the degree of the disease, and the like. It is recommended that the amount of the compound be about 0.1 to 2000 mg, preferably about 0.5 to about 800 mg, particularly preferably about 1.0 to about 500 mg per day, for adults, divided into 1 to 4 times a day, for example, on an empty stomach. can do.
- vacuolating toxin neutralizing agent obtained in Example 2 is dissolved in 500 ml of a 10% aqueous ethanol solution, and the ultrafiltration membrane having a molecular weight cutoff of 5,000 becomes 1.0 kg / cm 2 at room temperature to 20 ml. Processed. The obtained upper residue was freeze-dried to obtain 0.4 g of a vacuolating toxin neutralizer as a flesh-colored powder having an odorless and slightly bitter taste. When this powder is analyzed by HPLC under the conditions shown below, it has a characteristic mouth mass diagram as shown in Fig. 3. Method) yielded a value of 40.6% in terms of catechin content.
- Lactose 50 O g
- a candy was prepared according to a conventional method using the above components in each part by weight. Note that, instead of the substance obtained according to Example 5, candies to which the substances obtained according to Examples 1, 2, 3, 4, and 6 were respectively added were similarly obtained.
- Juices were prepared using the above parts by weight of each component according to a conventional method. It should be noted that instead of the substance obtained according to Example 5, juices to which the substances obtained according to Examples 1, 2, 3, 4, and 6 were added were also obtained.
- Cookies were prepared according to a conventional method using the above components in each part by weight. Note that instead of the substance obtained according to Example 5, cookies obtained by adding the substances obtained according to Examples 1, 2, 3, 4, and 6 respectively were obtained similarly.
- AZ-521 cells, a human gastric cancer-derived cell line, or G401 cells, a human kidney cancer-derived cell line were adjusted to a suspension of 2.0 ⁇ 10 5 cells / ml. After dispensing 100/1 into a 96-well plate, the plate was left overnight to prepare a monolayer film of each cell. To this was added a mixture of a constant concentration of vacuolated toxin and various concentrations of the neutralizing agent of vacuolar gizzard toxin obtained in Example 5 or 6, after incubation at 37 ° (30 minutes). the final concentration is 120 nM, final concentration of example 5 or 6 was 0-100 g / ml.
- Adjusting the G401 cells is AZ-521 cells or human kidney cancer-derived cell line is a human gastric cancer derived cell line in a suspension of 2.0 x i0 5 cells / ml.
- the 100 ⁇ 1 was dispensed into a 96-well plate, and left overnight to prepare a monolayer film of each cell.
- Various concentrations of pyotin-labeled vacuolated toxin and a constant concentration of the vacuolated toxin neutralizing agent obtained in Example 5 or 6 were used37. (After 30 minutes incubation, the cells were added to the cell monolayer. The final concentration of vacuolated toxin was 0-100 nM, and the final concentration of Examples 5 or 6 was 10 zg / ml.
- Example 5 To a 4-week-old C57BL / 6J mouse fasted for 24 hours (ItoR alone), 5 g of vacuolated toxin per 10 g of body weight and 50 to 250 zg of Example 5 were administered using an oral probe. Animals were housed individually in individual gauges, and 48 hours after administration, the stomach was removed. The excised specimen was fixed in 10% formalin, and stereoscopic observation was performed before and after that. The fixed specimens were stained with hematoxylin and eosin, and the degree of gastric injury was scored according to the method of Ghiara et al. (Ghiara.P., Et al. Infect.Immun. 63, 4154-4160. (1995)). evaluated. The results are shown in Table 1. Example 5 significantly suppressed gastric injury. ⁇ Table 1 Number Sample Gastrointestinal Damage Score _
- the neutralizing agent for vacuolated toxin of the present invention has an effect of detoxifying vacuolar toxin, and is therefore effective in preventing and treating infectious diseases using vacuolated toxin as a pathogenic factor.
- the product of the present invention can be commercialized as a prophylactic / therapeutic agent for infectious diseases using a vacuolating toxin as a pathogenic factor, a biochemical experimental reagent, and the like.
- H. pylori examples include gastric ulcer, duodenal ulcer, gastritis, gastric cancer, and MALT lymphoma.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/574,482 US20070009619A1 (en) | 2003-10-02 | 2004-10-04 | Neutralizing agent for cavitating toxin |
CN2004800288070A CN1863524B (zh) | 2003-10-02 | 2004-10-04 | 空泡毒素中和剂 |
JP2005514515A JPWO2005032542A1 (ja) | 2003-10-02 | 2004-10-04 | 空胞化毒素中和剤 |
US12/041,550 US20080275109A1 (en) | 2003-10-02 | 2008-03-03 | Neutralizing agent for vacuolating toxin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-344433 | 2003-10-02 | ||
JP2003344433 | 2003-10-02 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/041,550 Continuation US20080275109A1 (en) | 2003-10-02 | 2008-03-03 | Neutralizing agent for vacuolating toxin |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005032542A1 true WO2005032542A1 (ja) | 2005-04-14 |
Family
ID=34419387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/014979 WO2005032542A1 (ja) | 2003-10-02 | 2004-10-04 | 空胞化毒素中和剤 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20070009619A1 (ja) |
JP (1) | JPWO2005032542A1 (ja) |
KR (1) | KR100803375B1 (ja) |
CN (1) | CN1863524B (ja) |
TW (1) | TWI279231B (ja) |
WO (1) | WO2005032542A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007085868A (ja) * | 2005-09-21 | 2007-04-05 | Asahi Breweries Ltd | 飲食品中のポリフェノールの定量分析方法、定量分析装置および飲食品の設計方法 |
EP1920777A1 (de) * | 2006-11-13 | 2008-05-14 | Aslieh Dr. Nookandeh-Baumgärtner | Extraktionsverfahren zur klassifizierten Gewinnung und Trennung von pflanzlichen Inhaltsstoffen und deren Verwendung |
JPWO2006115123A1 (ja) * | 2005-04-19 | 2008-12-18 | アサヒビール株式会社 | ウィルス不活化剤 |
WO2014156450A1 (ja) * | 2013-03-28 | 2014-10-02 | サントリーホールディングス株式会社 | ホップ苞を使用したビールテイスト飲料の製造方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103570664B (zh) * | 2013-11-13 | 2015-07-01 | 长沙蓝威生物制品有限公司 | 一种从越橘中提取原花青素的方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6277390A (ja) * | 1985-07-19 | 1987-04-09 | イディビ・ホールディング・ソチエタ・ペル・アツィオーニ | プロアントシアニジンa2の製法、医薬組成物およびそれらの治療用途 |
JPH1025247A (ja) * | 1996-07-10 | 1998-01-27 | Asahi Breweries Ltd | 胃炎、胃・十二指腸潰瘍の予防及び治療剤 |
JPH10218769A (ja) * | 1997-02-06 | 1998-08-18 | Kikkoman Corp | 抗潰瘍剤 |
JPH11180888A (ja) * | 1997-12-24 | 1999-07-06 | Otsuka Pharmaceut Co Ltd | ヘリコバクター・ピロリ菌用の抗菌剤、感染予防剤および食品 |
JP2000506901A (ja) * | 1996-04-02 | 2000-06-06 | マーズ・インコーポレイテツド | カカオ抽出化合物及び同一物を製造及び使用するための方法 |
JP2000159669A (ja) * | 1998-11-26 | 2000-06-13 | Mikoo:Kk | ウレアーゼ阻害剤及びこれを含有する医薬及び食品組成物並びにウレアーゼ活性測定方法 |
WO2002078726A1 (fr) * | 2001-03-28 | 2002-10-10 | Asahi Breweries,Ltd. | Neutralisant de proteotoxines |
JP2003026587A (ja) * | 2001-07-11 | 2003-01-29 | Nobuo Yamaguchi | ヘリコバクター・ピロリ菌に対する除菌剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09221484A (ja) * | 1996-02-14 | 1997-08-26 | Kikkoman Corp | プロアントシアニジンの製造法 |
US5972985A (en) * | 1997-11-03 | 1999-10-26 | Cytos Pharmaceuticals, Llc | Histidine containing nutriceutical compositions |
US20030161841A1 (en) * | 2002-02-01 | 2003-08-28 | Kazuo Sakuma | Preventive and therapeutic agents for microbe-related syndromes including HIV |
-
2004
- 2004-09-30 TW TW093129616A patent/TWI279231B/zh active
- 2004-10-04 KR KR1020067006399A patent/KR100803375B1/ko not_active IP Right Cessation
- 2004-10-04 US US10/574,482 patent/US20070009619A1/en not_active Abandoned
- 2004-10-04 CN CN2004800288070A patent/CN1863524B/zh not_active Expired - Fee Related
- 2004-10-04 JP JP2005514515A patent/JPWO2005032542A1/ja active Pending
- 2004-10-04 WO PCT/JP2004/014979 patent/WO2005032542A1/ja active Application Filing
-
2008
- 2008-03-03 US US12/041,550 patent/US20080275109A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6277390A (ja) * | 1985-07-19 | 1987-04-09 | イディビ・ホールディング・ソチエタ・ペル・アツィオーニ | プロアントシアニジンa2の製法、医薬組成物およびそれらの治療用途 |
JP2000506901A (ja) * | 1996-04-02 | 2000-06-06 | マーズ・インコーポレイテツド | カカオ抽出化合物及び同一物を製造及び使用するための方法 |
JPH1025247A (ja) * | 1996-07-10 | 1998-01-27 | Asahi Breweries Ltd | 胃炎、胃・十二指腸潰瘍の予防及び治療剤 |
JPH10218769A (ja) * | 1997-02-06 | 1998-08-18 | Kikkoman Corp | 抗潰瘍剤 |
JPH11180888A (ja) * | 1997-12-24 | 1999-07-06 | Otsuka Pharmaceut Co Ltd | ヘリコバクター・ピロリ菌用の抗菌剤、感染予防剤および食品 |
JP2000159669A (ja) * | 1998-11-26 | 2000-06-13 | Mikoo:Kk | ウレアーゼ阻害剤及びこれを含有する医薬及び食品組成物並びにウレアーゼ活性測定方法 |
WO2002078726A1 (fr) * | 2001-03-28 | 2002-10-10 | Asahi Breweries,Ltd. | Neutralisant de proteotoxines |
JP2003026587A (ja) * | 2001-07-11 | 2003-01-29 | Nobuo Yamaguchi | ヘリコバクター・ピロリ菌に対する除菌剤 |
Non-Patent Citations (1)
Title |
---|
KASAI H. ET AL.: "Cranberry ni yoru kansensho no yobo to chiryo", FOOD STYLE 21, vol. 5, no. 12, 2001, pages 67 - 69, XP002987046 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2006115123A1 (ja) * | 2005-04-19 | 2008-12-18 | アサヒビール株式会社 | ウィルス不活化剤 |
JP2007085868A (ja) * | 2005-09-21 | 2007-04-05 | Asahi Breweries Ltd | 飲食品中のポリフェノールの定量分析方法、定量分析装置および飲食品の設計方法 |
JP4746391B2 (ja) * | 2005-09-21 | 2011-08-10 | アサヒビール株式会社 | 飲食品の機能性および/または呈味性の設計方法および飲食品 |
EP1920777A1 (de) * | 2006-11-13 | 2008-05-14 | Aslieh Dr. Nookandeh-Baumgärtner | Extraktionsverfahren zur klassifizierten Gewinnung und Trennung von pflanzlichen Inhaltsstoffen und deren Verwendung |
WO2008058694A1 (de) * | 2006-11-13 | 2008-05-22 | Aslieh Nookandeh-Baumgaertner | Extraktionsverfahren zur klassifizierten gewinnung und trennung von pflanzlichen inhaltsstoffen und deren verwendung |
WO2014156450A1 (ja) * | 2013-03-28 | 2014-10-02 | サントリーホールディングス株式会社 | ホップ苞を使用したビールテイスト飲料の製造方法 |
US10597618B2 (en) | 2013-03-28 | 2020-03-24 | Suntory Holdings Limited | Method for producing beverage having beer taste using hop bract |
Also Published As
Publication number | Publication date |
---|---|
TW200522973A (en) | 2005-07-16 |
JPWO2005032542A1 (ja) | 2007-11-15 |
US20070009619A1 (en) | 2007-01-11 |
US20080275109A1 (en) | 2008-11-06 |
TWI279231B (en) | 2007-04-21 |
KR20060058729A (ko) | 2006-05-30 |
CN1863524A (zh) | 2006-11-15 |
CN1863524B (zh) | 2010-10-06 |
KR100803375B1 (ko) | 2008-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007091631A (ja) | 抗ピロリ菌剤及びこれを含有する飲食物 | |
JP5167461B2 (ja) | 炎症性腸疾患予防剤 | |
JPWO2005074961A1 (ja) | 体脂肪調整剤 | |
JP4521703B2 (ja) | ホップより得られるリパーゼ阻害剤 | |
US20080275109A1 (en) | Neutralizing agent for vacuolating toxin | |
AU2003289063B2 (en) | Process for producing hop glume polyphenol | |
KR101645721B1 (ko) | 위장질환 예방 및 치료용 유향 함유 조성물 | |
JP4313045B2 (ja) | 蛋白質毒素中和剤 | |
KR102114271B1 (ko) | 금어초 추출물을 유효성분으로 포함하는 항염증용 약학적 조성물 | |
JP2005206493A (ja) | 抗ヘリコバクター・ピロリ剤 | |
JPWO2006115123A1 (ja) | ウィルス不活化剤 | |
JP2006193501A (ja) | アディポネクチン調節剤、それを含有する飲食品、食品添加物及び医薬 | |
WO2006064761A1 (ja) | アディポネクチン調節剤、それを含有する飲食品、食品添加物及び医薬 | |
US8658226B2 (en) | Agent having anti-Helicobacter pylori activity | |
JP4541662B2 (ja) | 抗ピロリ菌組成物 | |
US20140328911A1 (en) | Compositions comprising pomegranate polyphenols in combination with erectile dysfunction-treating compounds, and methods of treating erectile dysfunction therewith | |
JP2006290794A (ja) | 抗ヘリコバクター・ピロリ活性を有する植物発酵物 | |
KR101487742B1 (ko) | 표고버섯과 천마 추출물을 포함하는 항산화 효능을 갖는 식품 조성물 | |
KR20180134657A (ko) | 미성숙 감으로부터 폴리페놀을 추출하는 방법 | |
AU2007315980B2 (en) | Composition for the treatment of gastrointestinal diseases | |
EP3110432A1 (en) | Compositions for use in the treatment of mucositis and/or stomatitis | |
JP5066394B2 (ja) | ゲンクワニン5−O−β−プリメベロシドの抽出方法 | |
JP2009292766A (ja) | 血糖値上昇抑制剤および血糖値上昇抑制のための食品。 | |
JP2005263766A (ja) | 抗潰瘍用組成物 | |
JP2005206502A (ja) | アポトーシス誘導剤、これを含有する飲食品及び薬品並びにアポトーシス誘導剤の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480028807.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005514515 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067006399 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007009619 Country of ref document: US Ref document number: 10574482 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067006399 Country of ref document: KR |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 10574482 Country of ref document: US |